Cited by 44Pharmaceutical Practices and Patient OutcomesPain Management and Opioid UseInflammatory mediators and NSAID effects

Impact of potential inappropriate NSAIDs use in chronic pain

Open access
Ussai, Silvia, Miceli, Luca, Pisa, Federica, Bednarova, Rym, Petelin, Riccardo, Della Rocca, Giorgio, Giordano, Antonio·2015·Drug Design, Development and Therapy

Abstract

Pain remains one of the main reasons for medical consultation worldwide: moderate- to severe-intensity pain occurs in 19% of adult Europeans, seriously affecting the quality of their social and working lives. Nonsteroidal anti-inflammatory drugs (NSAIDs) are not recommended for long-term use and a careful surveillance to monitor for toxicity and efficacy is critical. This study aims to assess: 1) the pattern of use of NSAIDs and opioids in a population covered by a cloud-based pharmacovigilance surveillance system; and 2) potential inappropriate use. A retrospective 18-months systematic analysis on patients' pain treatment was performed. The primary endpoint was evaluating the prevalence of NSAIDs and opioids use and the duration of therapy regimen. The secondary endpoint was to investigate the prevalence of NSAIDs taken for >21 consecutive days concomitant with drugs for peptic ulcer and gastroesophageal reflux disease (GORD) or antiplatelet drugs. The yearly cost for individual users of concomitant NSAIDs for more than 21 consecutive days and of GORD medications has been estimated. A total of 3,050 subjects with chronic pain were enrolled; 97% of them took NSAIDs for >21 consecutive days; about one-fourth of these users also received drugs for peptic ulcer and GORD (Anatomical Therapeutic Chemical code A02B). The yearly cost foran individual who uses NSAIDs for >21 consecutive days as well as concomitant GORD medications is 61.23 euros. In total, 238 subjects (8%) using NSAIDs for >21 days also received one antiplatelet agent. About 11% of subjects received opioids at least once and only 2% of them carried on the therapy for more than 90 consecutive days. In evaluating the escalation in dosage as a proxy of dependence risk, this study shows no dosage escalation in our cohort of chronic pain population - that is to say we show no risk of dependence.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/dddt.s80686

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Current research suggests that inappropriate NSAID prescribing is common and needs to be addressed urgently to improve patient safety.

    “Current research suggests that inappropriate NSAID prescribing is common and needs to be addressed urgently to improve patient safety [45].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [17]Drug Allergy: Diagnosis and Management of Drug Allergy in Adults, Children and Young People National Clinical Guideline Centre (UK) 2014 9 25340226

Cited by

Sorted by citations

Authors
Ussai, S., Miceli, L., Pisa, F., Bednarova, R., Petelin, R., Della Rocca, G., & Giordano, A.
Affiliations
  • University of Siena (IT)
  • University of Udine (IT)
Corresponding author
Ussai, Silvia
Venue
Drug Design, Development and Therapy
Published
2015-04
Volume
9
Pages
2073
ISSN
1177-8881 (ISSN-L)
OpenAlex
W1996589062
Cited by
44
References
21
Citations by year
2026: 5 · 2025: 2 · 2024: 6 · 2023: 3 · 2022: 6 · 2021: 4 · 2020: 3 · 2019: 1 · 2018: 5 · 2017: 4 · 2016: 1 · 2015: 4
FWCI
2.34
Type
journal article
Language
en
Open access
Locations
  • Drug Design Development and Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Institutional Research Information System (University of Udine) (submittedVersion, cc-by-nc-nd)
  • TUScholarShare (Temple University) (submittedVersion, cc-by-nc)
  • Use Siena air (University of Siena) (submittedVersion)
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
  • Health Sciences › Medicine › Pharmacology › Inflammatory mediators and NSAID effects
Keywords
chronic pain, nonsteroidal anti-inflammatory drugs, inappropriate medication use, opioid use, peptic ulcer, gastroesophageal reflux disease, antiplatelet agents, drug interactions, pharmacovigilance, health care costs, dose escalation
MeSH terms
Adult, Analgesics, Opioid, Anti-Inflammatory Agents, Non-Steroidal, Drug Utilization, Female, Gastroesophageal Reflux, Humans, Male, Middle Aged, Peptic Ulcer, Platelet Aggregation Inhibitors, Retrospective Studies, Cohort Studies, Prevalence, Drug Costs, Endpoint Determination, Inappropriate Prescribing, Chronic Pain, Pharmacovigilance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review